Identification and Characterization of Two Novel Mutations (Q421K and R123P) in Congenital Factor XII Deficiency

Summary

The factor XII genes of two unrelated factor XII-deficient Japanese families were screened, and two novel mutations were identified. A heterozygous mutation (Q421K) was identified in the gene of a cross-reacting material (CRM)-negative patient with reduced FXII activity (entitled Case 1). No mutations were discovered in the other allele. Case 2 was a CRM-negative patient with severe FXII deficiency. In this case, a homozygous mutation (R123P) was discerned. Expression studies in Chinese Hamster Ovary (CHO) cells demonstrated accumulation of mutant Q421K factor XII in the cell, and insufficient secretion, while the R123P mutant showed lower levels of accumulation than wild-type, and no evidence of secretion in culture supernatant. In the presence of proteasome inhibitor, all types of FXII (wild-type, Q421K, R123P) accumulated in the cells. Protease protection experiments using the microsomal fraction of these cell lines demonstrated that while 20% wild-type FXII (total wild-type:100%) and 10% R123P mutant (total R123P-type: 40%) were resistant to treatment with trypsin, 50% Q421K-type FXII (total Q421K-type:130%) remained resistant to digestion. From these results, we conclude that Q421K is less susceptible to proteasome degradation than wild-type, but is unable to exit the ER efficiently, resulting in insufficient secretion phenotype. In contrast, R123P is susceptible to proteasome degradation and is not secreted.

Keywords

FXII deficiency - mutation - proteasome

• References

• 1 Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemost 1987; 13: 50-68.
• 2 Ratonoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting factor fraction of plasma. J Clin Invest 1955; 34: 602.
• 3 Saito H. Contact factors in health and disease. Semin Thromb Hemost 1987; 13: 36-49.
• 4 Bernardi F, Marchetti G, Patracchini P, del Senno L, Tripodi M, Fantoni A, Bartolai S, Vannini F, Felloni L, Rossi L, Panicucchi F, Conconi F. Factor XII gene alteration in Hageman trait detected by TaqI restriction enzyme. Blood 1987; 69: 1421-4.
• 5 Schloesser M, Zeerleder S, Lutze G, Halbmayer WM, Hofferbert S, Hinney B, Koestering H, Lammle B, Pindur G, Thies K, Kohler M, Engel W. Mutations in the human factor XII gene. Blood 1997; 90: 3967-77.
• 6 Kondo S, Tokunaga F, Kawano S, Oono Y, Kumagai S, Koide T. Factor XII Tenri, a novel cross-reacting material negative factor XII deficiency, occurs through a proteasome-mediated degradation. Blood 1999; 93: 4300-8.
• 7 Dati F, Barthels M, Conard J, Fluckiger J, Girolami A, Hanseler E, Huber J, Keller F, Kolde HJ, Muller-Berghaus G, Samama M, Thiel W. Multicenter evaluation of a chromogenic substrate method for photometric determination of prothrombin time. Thromb Haemost 1987; 58: 856-65.
• 8 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52.
• 9 Cool DE, MacGillivray RT. Characterization of the human blood coagulation factor XII gene. Intron/exon gene organization and analysis of the 5′-flanking region. J Biol Chem 1987; 262: 13662-73.
• 10 Cool DE, Edgell CJ, Louie GV, Zoller MJ, Brayer GD, MacGillivray RT. Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa. J Biol Chem 1985; 260: 13666-76.
• 11 Pixley RA, Colman RW. A monoclonal antibody recognizing an eicosa-peptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation. Adv Exp Med Biol 1989; 247A: 473-6.
• 12 Kanaji S, Iwahashi J, Kida Y, Sakaguchi M, Mihara K. Characterization of the signal that directs tom20 to the mitochondrial outer membrane. J Cell Biol 2000; 151: 277-88.
• 13 Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N, Niho Y. A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-4.
• 14 Katsumi A, Senda T, Yamashita Y, Yamazaki T, Hamaguchi M, Kojima T, Kobayashi S, Saito H. Protein C Nagoya, an elongated mutant of protein C, is retained within the endoplasmic reticulum and is associated with GRP78 and GRP94. Blood 1996; 87: 4164-75.
• 15 Liu Y, Choudhury P, Cabral CM, Sifers RN. Oligosaccharide modification in the early secretory pathway directs the selection of a misfolded glyco-protein for degradation by the proteasome. J Biol Chem 1999; 274: 5861-7.
• 16 Nichols WC, Seligsohn U, Zivelin A, Terry VH, Hertel CE, Wheatley MA, Moussalli MJ, Hauri HP, Ciavarella N, Kaufman RJ, Ginsburg D. Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 1998; 93: 61-70.
• 17 Semba U, Yamamoto T, Kunisada T, Shibuya Y, Tanase S, Kambara T, Okabe H. Primary structure of guinea-pig Hageman factor: sequence around the cleavage site differs from the human molecule. Biochim Biophys Acta 1992; 1159: 113-21.
• 18 Shibuya Y, Semba U, Okabe H, Kambara T, Yamamoto T. Primary structure of bovine Hageman factor (blood coagulation factor XII): comparison with human and guinea pig molecules. Biochim Biophys Acta 1994; 1206: 63-70.